Although antagonist TIM-3 or agonistic CD137 antibodies can promote the rejection of some murine tumors, however, poorly immunogenic tumors such as ID8 ovarian cancer do not respond to antibody therapy alone [28]. This evidence concerns the gene TNFRSF9 and ovarian cancer.